N-substituted hydroxylamine derivatives with carbon-based leaving groups
US-2016115148-A1 · Apr 28, 2016 · US
US9862699B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9862699-B2 |
| Application number | US-201615290872-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 11, 2016 |
| Priority date | Oct 17, 2011 |
| Publication date | Jan 9, 2018 |
| Grant date | Jan 9, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.
Opening claim text (preview).
What is claimed is: 1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: X and Z are independently —O— or —S—; Y is —CR 5 R 6 —; R is selected from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 1 -C 8 alkoxy, C 5 -C 10 aryl, —C(═O)R 7 , —C(═S)R 7 , —C(═NR 7 )R 8 , and —C(═NOR 7 )R 8 , wherein the alkyl, alkenyl, alkynyl, alkoxy and aryl are unsubstituted or substituted with one or more substituents; and R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are independently selected from —H, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 5 -C 10 aryl, C 5 -C 10 heterocycloalkyl, C 5 -C 10 heterocycloalkenyl, and C 5 -C 10 heteroaryl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl and heteroaryl are unsubstituted or substituted with one or more substituents. 2. The compound of claim 1 , wherein R is C 1 -C 8 alkyl, wherein the alkyl is unsubstituted or substituted with one or more substituents. 3. The compound of claim 1 , wherein R is C 1 -C 4 alkyl. 4. The compound of claim 1 , wherein R is —C(═NOR 5 )R 6 . 5. The compound of claim 1 , wherein R is —C(═NOR 5 )R 6 ; and R 5 and R 6 are independently C 1 -C 4 alkyl. 6. The compound of any one of claims 1 , and 2 to 5 , wherein X and Z are each —O—. 7. The compound of claim 1 , wherein the compound is: 8. A pharmaceutical composition comprising: a compound of claim 1 ; and a pharmaceutically acceptable excipient. 9. A kit comprising: a compound of claim 1 ; and instructions for treating a condition that is responsive to nitroxyl therapy. 10. A pharmaceutical composition comprising: a compound of claim 7 ; and a pharmaceutically acceptable excipient. 11. A kit comprising: a compound of claim 7 ; and instructions for treating a condition that is responsive to nitroxyl therapy.
Drugs for disorders of the cardiovascular system · CPC title
Antihypertensives · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.